Frontiers in pharmacology
Cost-effectiveness of aficamten for obstructive hypertrophic cardiomyopathy: a model-based analysis from the perspective of the Chinese healthcare system
Par Zhai F, Li H, Jiang C et 3 autres.
Contenu en anglais
Résumé
Background
To evaluate the cost-effectiveness of aficamten plus standard of care (SoC) versus SoC alone for patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) from the perspective of the Chinese healthcare system.
Methods
A four-state Markov model based on the phase III SEQUOIA-HCM trial was developed to simulate lifetime outcomes. The first 24 weeks were modeled using trial data, followed by 4-week cycles for long-term extrapolation. Based on FOREST-HCM, the incremental treatment effect of aficamten was assumed to persist through week 96 and then linearly wane to complete loss by year 3. Costs and health outcomes were discounted at 4.5% annually. Model uncertainty was assessed using one-way sensitivity analysis, probabilistic sensitivity analysis, and scenario analyses.